Bone pain: current and future treatments

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Bone pain : current and future treatments. / Frost, Charlotte Ørsted; Hansen, Rikke Rie; Heegaard, Anne-Marie.

In: Current Opinion in Pharmacology, Vol. 28, 06.2016, p. 31-7.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Frost, CØ, Hansen, RR & Heegaard, A-M 2016, 'Bone pain: current and future treatments', Current Opinion in Pharmacology, vol. 28, pp. 31-7. https://doi.org/10.1016/j.coph.2016.02.007

APA

Frost, C. Ø., Hansen, R. R., & Heegaard, A-M. (2016). Bone pain: current and future treatments. Current Opinion in Pharmacology, 28, 31-7. https://doi.org/10.1016/j.coph.2016.02.007

Vancouver

Frost CØ, Hansen RR, Heegaard A-M. Bone pain: current and future treatments. Current Opinion in Pharmacology. 2016 Jun;28:31-7. https://doi.org/10.1016/j.coph.2016.02.007

Author

Frost, Charlotte Ørsted ; Hansen, Rikke Rie ; Heegaard, Anne-Marie. / Bone pain : current and future treatments. In: Current Opinion in Pharmacology. 2016 ; Vol. 28. pp. 31-7.

Bibtex

@article{5ee67df6018143269844be8586d04d7c,
title = "Bone pain: current and future treatments",
abstract = "Skeletal conditions are common causes of chronic pain and there is an unmet medical need for improved treatment options. Bone pain is currently managed with disease modifying agents and/or analgesics depending on the condition. Disease modifying agents affect the underlying pathophysiology of the disease and reduce as a secondary effect bone pain. Antiresorptive and anabolic agents, such as bisphosphonates and intermittent parathyroid hormone (1-34), respectively, have proven effective as pain relieving agents. Cathepsin K inhibitors and anti-sclerostin antibodies hold, due to their disease modifying effects, promise of a pain relieving effect. NSAIDs and opioids are widely employed in the treatment of bone pain. However, recent preclinical findings demonstrating a unique neuronal innervation of bone tissue and sprouting of sensory nerve fibers open for new treatment possibilities.",
keywords = "Journal Article, Review",
author = "Frost, {Charlotte {\O}rsted} and Hansen, {Rikke Rie} and Anne-Marie Heegaard",
note = "Copyright {\textcopyright} 2016 Elsevier Ltd. All rights reserved.",
year = "2016",
month = jun,
doi = "10.1016/j.coph.2016.02.007",
language = "English",
volume = "28",
pages = "31--7",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier Ltd. * Current Opinion Journals",

}

RIS

TY - JOUR

T1 - Bone pain

T2 - current and future treatments

AU - Frost, Charlotte Ørsted

AU - Hansen, Rikke Rie

AU - Heegaard, Anne-Marie

N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.

PY - 2016/6

Y1 - 2016/6

N2 - Skeletal conditions are common causes of chronic pain and there is an unmet medical need for improved treatment options. Bone pain is currently managed with disease modifying agents and/or analgesics depending on the condition. Disease modifying agents affect the underlying pathophysiology of the disease and reduce as a secondary effect bone pain. Antiresorptive and anabolic agents, such as bisphosphonates and intermittent parathyroid hormone (1-34), respectively, have proven effective as pain relieving agents. Cathepsin K inhibitors and anti-sclerostin antibodies hold, due to their disease modifying effects, promise of a pain relieving effect. NSAIDs and opioids are widely employed in the treatment of bone pain. However, recent preclinical findings demonstrating a unique neuronal innervation of bone tissue and sprouting of sensory nerve fibers open for new treatment possibilities.

AB - Skeletal conditions are common causes of chronic pain and there is an unmet medical need for improved treatment options. Bone pain is currently managed with disease modifying agents and/or analgesics depending on the condition. Disease modifying agents affect the underlying pathophysiology of the disease and reduce as a secondary effect bone pain. Antiresorptive and anabolic agents, such as bisphosphonates and intermittent parathyroid hormone (1-34), respectively, have proven effective as pain relieving agents. Cathepsin K inhibitors and anti-sclerostin antibodies hold, due to their disease modifying effects, promise of a pain relieving effect. NSAIDs and opioids are widely employed in the treatment of bone pain. However, recent preclinical findings demonstrating a unique neuronal innervation of bone tissue and sprouting of sensory nerve fibers open for new treatment possibilities.

KW - Journal Article

KW - Review

U2 - 10.1016/j.coph.2016.02.007

DO - 10.1016/j.coph.2016.02.007

M3 - Journal article

C2 - 26940053

VL - 28

SP - 31

EP - 37

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

ER -

ID: 169740805